SHARESIFT
Healthcare · data ~15-min delayed
97.5 USD +0.84%
| Price | 97.5 USD |
| Day change | +0.84% |
| Market cap | 168.71B |
| 52-week range | 81.97 – 135.24 |
| P/E (trailing) | 31.6 |
| Dividend yield | 2.58% |
| Payout ratio | 78.96% |
| Return on equity | 10.58% |
| Debt / equity | 63% |
| Beta | 0.59 |
| Sector | Healthcare |
| Value score | 22 / 100 |
Abbott Laboratories (ABT) scores 22/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 31.6 times trailing earnings and is classified in Healthcare. The dividend yield is 2.58%, paid from 79% of earnings. Return on equity is 11%, with debt at 63% of equity. On its filings it passes 6 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 6 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 4.71 — Safe zone.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.